Abstract
Mature microRNAs (miRNAs), derived through cleavage of pre-miRNAs by the Dicer1 enzyme, regulate protein expression in many cell-types including cells in the pancreatic islets of Langerhans. To investigate the importance of miRNAs in mouse insulin secreting β-cells, we have generated mice with a β-cells specific disruption of the Dicer1 gene using the Cre-lox system controlled by the rat insulin promoter (RIP). In contrast to their normoglycaemic control littermates (RIP-Cre+/− Dicer1 Δ/wt), RIP-Cre+/− Dicer1flox/flox mice (RIP-Cre Dicer1 Δ/Δ) developed progressive hyperglycaemia and full-blown diabetes mellitus in adulthood that recapitulated the natural history of the spontaneous disease in mice. Reduced insulin gene expression and concomitant reduced insulin secretion preceded the hyperglycaemic state and diabetes development. Immunohistochemical, flow cytometric and ultrastructural analyses revealed altered islet morphology, marked decreased β-cell mass, reduced numbers of granules within the β-cells and reduced granule docking in adult RIP-Cre Dicer1 Δ/Δ mice. β-cell specific Dicer1 deletion did not appear to disrupt fetal and neonatal β-cell development as 2-week old RIP-Cre Dicer1 Δ/Δ mice showed ultrastructurally normal β-cells and intact insulin secretion. In conclusion, we have demonstrated that a β-cell specific disruption of the miRNAs network, although allowing for apparently normal β-cell development, leads to progressive impairment of insulin secretion, glucose homeostasis and diabetes development.
Introduction
The insulin-secreting function of pancreatic β-cells is one of the most critical aspects in the development of diabetes [1] and insulin release from pancreatic β-cells plays an essential role in blood glucose homeostasis [2]. Insulin is synthesized through transcription and translation of the insulin gene into preproinsulin and cleavage of the signal peptide and the C-peptide during the maturation process [3]. Both transcription and translation of insulin are glucose-dependent processes. Insulin gene expression is increased through glucose-dependent activation of specific transcription factors [4] and posttranscriptional regulation of insulin involves glucose-dependent insulin mRNA stabilization and translation [5]. Mature insulin can remain within the insulin granules for several days [6] before it is transported out to the plasma membrane. A large proportion of the granules reside in a reserve pool within the β-cell whereas <1% of the granules are docked and primed at the plasma membrane [7]. We and others have hypothesized that the release of primed granules correlates with the 1st phase insulin secretion while release of granules within the larger reserve pool constitutes the release during the 2nd phase insulin secretion [8], [9].
MicroRNAs are a class of 19–25 nucleotide (nt)-long noncoding RNA molecules that are involved in regulation of gene expression [10]. Mature miRNAs are processed from double-stranded hairpin precursors by Drosha and Dicer enzymes [11]. Only one Dicer enzyme is present in mammals and is responsible for the final step in miRNA processing [12]. Disruption of the catalytic process mediated by Dicer results in lack of mature miRNAs, leading to altered target gene expression [11]. Germline deletion of Dicer1 is embryonically lethal in mice [13], [14] and results in altered embryonic stem cell differentiation [15].
Several miRNAs regulating different parts of the insulin-secreting process have been identified. The β-cell enriched miRNA miR-375 has been demonstrated to influence insulin mRNA levels [16] as well as the exocytotic process [17]. Moreover, the level of miRNA-375, together with miRNA-127-3p and miR-184 is positively correlated to insulin mRNA levels in islets from human donors and the association between these miRNAs and β-cell function was deranged in islets from glucose intolerant donors [18]. MiR-375 has also been implicated in β-cell expansion and proliferation [19]. Recently, several other miRNAs including miR-24 and miR-182 was implicated to be important for insulin biosynthesis [20]. Other miRNAs directly regulating insulin secretion affecting the expression of proteins involved in the exocytotic process include miR-124a and miR-96 [21]. Indeed, it was recently shown that the predicted targets of a number of miRNAs overexpressed in the pancreatic islets of the type 2 diabetes model, Goto-Kakizaki rat, were shown to be enriched for genes with central roles in exocytosis, including Syntaxin-binding protein 1 (Stxbp1) shown experimentally to be a target of rno-miR-335 [22]. In addition, miRNAs have been suggested to contribute to fatty acid-induced β-cell dysfunction [23].
β-cell specific Dicer1 deletion controlled by the Pdx1 promoter results in aberrant pancreas development (specifically in the insulin-secreting β-cells) and neonatal death [24]. Inactivation of Dicer1 in adult life leads to development of diabetes due to reduced insulin expression [20]. However, the effect of progressive loss of Dicer 1 during life has not yet been determined. We have studied the role of miRNAs in β-cell function and in the development of diabetes in vivo by specifically deleting Dicer1 in pancreatic β-cells under the RIP-promoter. Our results show that disruption of miRNA processing in mouse pancreatic β-cells, while compatible with β-cell development, leads to defective insulin-secreting function and progressive overt diabetes mellitus.
Results
β-cell specific deletion of Dicer1 gene results in diabetes development
To investigate the effect of Dicer1 deficiency on diabetes development, we generated mice with a β-cell specific Dicer1 deletion from mid gestation (E9–11.5) using the Cre-lox system (RIP-Cre Dicer1Δ/Δ) by crossing RIP-Cre transgenic with Dicerflox/flox mice (Fig. 1A and B). The possibility of RIP-Cre mediated Dicer1 deletion in brain [25] and the possible effects in feeding behaviour and body weight was excluded by measuring Dicer1 expression and daily measurement of body weight (Fig. S1A–B). Feeding behavior, measured by controlling food consumption, also remained unchanged between the two mouse strains (Fig. S1C). The incidence of spontaneous diabetes was determined in RIP-Cre Dicer1Δ/Δ mice and control littermates (RIP-Cre Dicer1 wt/Δ) from 2 weeks of age. Mice were considered diabetic when blood glucose levels were ≥13.5 mmol/l on two consecutive measurements. The onset of diabetes was dated to the first of these two measurements. As shown in Fig. 1C, by 12 weeks of age, 80% of Dicer1 deficient mice (n = 70) developed diabetes and, by 25 weeks of age, 100% of mice were diabetic. Male mice (n = 33) developed diabetes faster compared to females (n = 37; p = 0.0005). Fig. 1D shows the measured plasma glucose levels in 4, 7 and 13 weeks old mice. Control littermate mice (n = 70) always remained normoglycaemic.
In vivo impairment of glucose homeostasis in RIP-Cre Dicer1 Δ/Δ mice
To investigate the efficiency of RIP-Cre Dicer1Δ/Δ β-cells to maintain in vivo glucose homeostasis after glucose challenge, we performed the intraperitoneal glucose tolerance test (ipGTT). No differences in glucose tolerance between RIP-Cre Dicer1Δ/Δ and control mice (Fig. 2A) were observed in 4–5 weeks old mice. By contrast, at 13 weeks of age, RIP-Cre Dicer1Δ/Δ mice showed extremely impaired glucose tolerance compared to control mice (P<0.0001, Fig. 2A).
Impaired insulin secretion precedes hyperglycaemia in RIP-Cre Dicer1Δ/Δ mice
To investigate the effects of the β-cell-specific Dicer1 deletion on insulin secretion in vitro, we performed batch-incubations of pancreatic islets. Islets were incubated at basal (1 mM) or stimulating (20 mM) glucose concentration for 1 hour. Insulin secretion in response to basal glucose concentration was normal in young (2 and 5 weeks old) RIP-Cre Dicer1Δ/Δ mice, but significantly reduced in 8 weeks old RIP-Cre Dicer1Δ/Δ mice (P<0.0001, Fig. 2C). Insulin secretion in response to 20 mM glucose was normal in 2 weeks old RIP-Cre Dicer1Δ/Δ mice, but reduced by over 70% in 5 and 8 weeks old RIP-Cre Dicer1Δ/Δ mice (P<0.0001, Fig. 2B and C). However, upon normalization for insulin content insulin secretion levels in 8 weeks old mice actually increased compared to those of controls (P<0.05, Fig. 2C). These results indicate a defect in either insulin production, β-cell survival or both in the RIP-Cre Dicer1Δ/Δ mice.
Dicer1 disruption in β-cells leads to morphological changes in pancreatic islets
The histological phenotype of the pancreatic islets was examined using H-E staining. The analysis performed on RIP-Cre Dicer1Δ/Δ and control pancreas at 5, 8, 11 and 25 weeks of age (Fig. 3) showed that islet morphology was clearly altered already at 5 weeks of age in RIP-Cre Dicer1Δ/Δ mice. In 25 weeks old RIP-Cre Dicer1Δ/Δ mice the number of islets was dramatically decreased and in general smaller compared to littermate controls.
Dicer1 disruption in β-cells leads to progressive decrease of insulin producing cells and total β-cell mass
To visualize insulin-producing cells in situ, we performed immunohistochemical analysis using confocal microscopy (Fig. 4). At 5 weeks of age, the insulin to glucagon ratio (R) was not significantly different between RIP-Cre Dicer1Δ/Δ (R = 3.3±0.7, n = 6) and control littermate mice (R = 4.9±1.1, n = 5). In 8 to 11 weeks old mice we observed a clear reduction of β-cells in RIP-Cre Dicer1Δ/Δ mice compared to control littermates with a relative increase in the number of α-cells, and the ratio was 0.8±0.2 (n = 12) in the RIP-Cre Dicer1Δ/Δ mice islets and 3.6±0.6 in control littermates (n = 12; p<0.001 control littermates vs RIP-Cre Dicer1Δ/Δ).
Both the morphological changes and the observed decrease in the β-cell to α-cell ratio in RIP-Cre Dicer1Δ/Δ islets could be related to a reduced number of β-cells. To more accurately quantify the frequency of pancreatic β- and α-cells, we performed flow cytometric analysis of dispersed islets on 8 to 11 weeks old RIP-Cre Dicer1Δ/Δ mice and age-matched control littermates using antibodies specific for insulin and glucagon. As shown in Fig. 5, we confirmed a significant reduction of β-cells (from 68±1% insulin positive cells in control littermates to 42±3% in RIP-Cre Dicer1Δ/Δ mice; P<0.001, n = 3) with a relative increase of α-cells (from 20±2% glucagon positive cells in control littermates to 38±5% in RIP-Cre Dicer1Δ/Δ mice; P<0.05, n = 3).
Based on these results, we next performed Optical Projection Tomography (OPT) [26] to study the total β-cell mass in whole-mounted pancreas 3-dimensionally. As shown in Fig. 6, there was no significant difference in total number of insulin-producing cells between RIP-Cre Dicer1Δ/Δ and control littermates at 5 weeks of age. However, we could undoubtedly demonstrate a significant reduction of total insulin-producing cells in RIP-Cre Dicer1Δ/Δ compared to littermate control mice in 8 and 12 week old mice. Quantification of the number of islets per pancreas in 8–12 week old mice revealed a significant decrease from 2300±451 islets/pancreas (N = 6 mice) in control mice to 1485±378 islets/pancreas (N = 6 mice; p = 0.0035 vs control mice) in RIP-Cre Dicer1Δ/Δ. Likewise, β-cell mass measured as β-cell volume per whole pancreas volume [26], [27] was reduced in 8 and 12 week old RIP-Cre Dicer1Δ/Δ mice by ≥50% compared with their control littermates of the same age (Fig. 6B).
Ultrastructural analysis reveals β-cell loss and reduction of β-cell secretory granules
To better characterize the consequences of Dicer1 disruption at single cell level, we performed transmission electron microscopy (TEM). In 11 weeks old RIP-Cre Dicer1Δ/Δ mice, the electron micrographs revealed an obvious reduction of the number of β-cells within the islets compared to the control islets. The electron micrographs indicated that the few remaining β-cells in RIP-Cre Dicer1Δ/Δ had less insulin granules than their control littermates (Fig. 7A). This was confirmed by ultrastructural analysis (Fig. 7B) which revealed ∼50% less granules in the RIP-Cre Dicer1Δ/Δ compared to the controls when measured as volume-density (Nv; Fig. 7B, left). This reduction was specific for the β-cells and could not be observed in non-β-cells (data not shown). The number of docked granules expressed as the surface density (Ns) was also severely reduced in β-cells from 11 week old RIP-Cre Dicer1Δ/Δ mice compared to control littermates (Fig. 7B, right). At 2 weeks of age this phenotypic feature had not appeared (Fig S2) and the β-cells in RIP-Cre Dicer1Δ/Δ mice had a similar granular volume density Nv and surface density Ns as control littermates (Fig. 7C).
Dicer1 knockdown dramatically reduce insulin gene expression in isolated β-cells
We next tested whether the level of Dicer1 deletion affect insulin expression in sorted β-cells. Purified islets from 6 to 8 weeks old non-diabetic RIP-Cre Dicer1Δ/Δ (n = 7) and control littermates (n = 7) were pooled and dissociated before being stained with Newport Green-Ac and sorted by flow cytometry as described in material and methods. The purity after sorting was >95% as determined by insulin staining and immunofluorescence microscopy (data not shown). In line with the data showed above, we could demonstrate by qPCR a 90% decrease of insulin gene expression in RIP-Cre Dicer1Δ/Δ compared to littermate control mice (Fig. 8 A). To verify that the knock-down of dicer effects miRNA expression we measured the expression of the β-cell specific miRNA, mir-375, and found that it was reduced by 70% in the RIP-Cre Dicer1Δ/Δ compared to littermate control mice (Fig. 8 B). This was accompanied by an accumulation of pri-miRNA-375 in the RIP-Cre Dicer1Δ/Δ β-cells (Fig. 8B).
To investigate the effect of Dicer1 knockdown on the global miRNA level, we hybridized total RNA from sorted β-cells of wildtype, Dicer1 flox/flox and RIP-Cre Dicer1Δ/Δ into locked nucleic acid (LNA)-based arrays. Owing to the limited starting material, we could only perform the experiments once for each sample and we generally observed low signal intensities from the arrays. Of the 60 quantifiable miRNA signals, 26 miRNAs were not detectable in RIP-Cre Dicer1Δ/Δ (Fig. S3). These include the islet-specific miR-375 and another abundant islet miRNA, miR-7a [28]. Surprisingly, 14 miRNAs were similarly expressed in the knockout animals as in the controls while 20 miRNAs were found to be exclusively expressed in the former (Fig. S3). Our array data indicate the existence of both Dicer1-dependent and -independent maturation pathway of miRNAs in line with previous studies [29], [30]. However, our array data cannot conclusively support the extent of a Dicer1-independent pathway without further validation.
No evidence for altered β-cell proliferation or apoptosis in RIP-Cre Dicer1Δ/Δ mice
To determine whether the observed phenotype of RIP-Cre Dicer1Δ/Δ was due to increased β-cell apoptosis that could be preceded or accompanied by an altered proliferative potential, we performed in situ TUNEL assay (Fig. 9A) and we stained pancreatic section with Ki67 specific antibodies (Fig. 9B). No detectable increased β-cell apoptosis could be observed in any of the strains at any time point. In addition, Ki67 staining did not differ in islets from RIP-Cre Dicer1Δ/Δ and control littermates (Fig. 9B).
Discussion
In this work, we demonstrate for the first time that targeted disruption of the Dicer1 gene specifically in β-cells leads to progressive reduction in insulin secretion, glucose tolerance and development of diabetes. Strikingly, 100% of RIP-Cre Dicer1Δ/Δ mice developed diabetes by 25 weeks of age indicating the importance of the miRNAs network for the proper function of insulin-producing cells and, in turn, for glucose metabolism. Both in vitro and in vivo studies demonstrate a decreased response to glucose stimulated insulin secretion in the RIP-Cre Dicer1Δ/Δ mice from 5 weeks of age. Prior to that, β-cell mass and function were not altered, suggesting that in our model disruption of Dicer1-dependent miRNA processing apparently does not affect the early stages of β-cell development. Indeed, insulin secretion in young mice, as well as the number of secretory granules, did not differ between RIP-Cre Dicer1Δ/Δ and littermates control mice.
While, our results partially affirm those observed by Morita et al. [31], who reports normal fetal and neonatal pancreatic development in Dicer1-hypomorphic mice that progress to morphological islet abnormalities only at 4 weeks of age. Our reported results contradict Lynn et al. [24] who observed no gross phenotype in mice driving Dicer1 deletion using the RIP promoter. One explanation for the discrepancy with our study could be the different genetic background of the mouse strains [32] or the extent of Dicer deletion. However, neither Dicer1 expression nor functional studies were performed in their mice with RIP-driven Dicer1 deletion [24]. Pdx1-driven Dicer1 deletion in β-cells had instead a profound effect in β-cell development [24]. The difference with our model is likely to be due to earlier expression of Pdx1 [33] as compared with the insulin genes [32], [34], therefore earlier ablation of Dicer1 may result in a more profound defect in β-cells reprogramming and differentiation.
What is the mechanism underlying β-cell mass reduction in the absence of the Dicer1 enzyme? Surprisingly, we could not observe any increase of β-cell apoptosis (measured by TUNEL in situ) or an altered β-cell proliferation based on Ki67 staining in RIP-Cre Dicer1Δ/Δ at any time point studied. However, we cannot exclude the possibility that β-cells undergo progressive apoptosis in a non-synchronized way posing a technical challenge in measuring cumulative cell death in situ at each specific time point. Alternatively, cell death could have occurred without the classical DNA single strands breaks measured by the TUNEL technique. Therefore, more studies are necessary to clarify this issue.
Interestingly, we observed not only reduction in the β-cell mass but a concomitant dramatic loss in insulin expression (Fig. 8) in the RIP-Cre Dicer1Δ/Δ mice with a reduced number of granules within β-cells (Fig. 7). This observation confirms the results recently published data where Dicer1 was depleted in β-cells in adulthood [20]. That the regulation of insulin expression is controlled by miRNAs demonstrate the importance of these molecules in the control of insulin secretion. The reduced number of granules in the β-cell (Fig. 7B) might in part be due to the reduced insulin expression. However, the fact that no accumulation of empty granules was observed indicates that miRNAs also are necessary for the processing of insulin granules. The observed number of docked granules can be a cause of the reduced number of total granules. However, it cannot totally be excluded that depletion of Dicer1 has a direct effect on the docking of granules due to that many miRNAs have been proven to be important for insulin exocytosis [35]. Indeed, the reduction in the number of docked granules (∼65%) in the RIP-Cre Dicer1Δ/Δ compared to control mice exceeds the reduction in the total number of granules (∼50%) indicating the importance of mature miRNAs in the regulation of the exocytotic process. Against this hypothesis is the observation that reduced glucose-stimulated insulin secretion in the RIP-Cre Dicer1Δ/Δ mice could entirely be explained by reduced islet insulin content (Fig. 2C) and glucose stimulated secretion as measured per insulin content was even significantly increased This would suggest that under the physiological condition of reduced insulin content, the RIP-Cre Dicer1Δ/Δ mice try to compensate by increasing processes involved in secretion. In such scenario, the reduced number of docked granules in the RIP-Cre Dicer1Δ/Δ mice is more likely associated with increased fusion of insulin granules (with less content in each granule) and failure of replenishment of docked granules.
In comparison with earlier published work where Dicer1 deletion was driven by the Pdx-promotor [24] or in adulthood under the RIP-promotor [20] our data (where Dicer1 is driven by the RIP-promotor earlier in life) demonstrate a broader phenotype. We observe not only reduction of insulin gene expression and concomitant reduced number of granules in the β-cells, but also altered islet morphology and reduced β-cells mass. This suggests that miRNAs control several important steps including insulin biosynthesis and β-cell survival. Further, Dicer1-dependent miRNAs are most likely controlling the islet architecture early in life although that the observed effects on β-cell survival are visible first around week 8 (See e.g. Fig. 4). Once Dicer1 is deleted in adulthood islet architecture stays intact [20]. Although we were not able to demonstrate an increase in the frequency of apoptotic cells in the islets of RIP-Cre Dicer1Δ/Δ mice, we cannot rule out the possibility that β-cell loss is due to increased cell death. Our model is indeed characterized by a progressive loss of β-cell mass, which in time results in full blown diabetes. It is well known that apoptotic cells are very rapidly eliminated by scavenger cells and it is therefore likely that non synchronized apoptosis accompanied by a rapid phagocytosis and elimination of apoptotic cells have hampered the possibility of detecting the increase in beta cell death that should be expected based on the phenotype of these mice.
Finally, our results highlight the role of miRNAs in diabetes development. It is conceivable that the fine-tuning regulation of gene expression mediated by miRNAs might have important implication in diabetes pathogenesis also in humans [36]. In support, we have recently published data indicating a disturbed miRNA network in islets from human glucose intolerant donors [18] and in the GK-rat [22]. Our mouse model suggests that several miRNAs are involved in the development of diabetes. Overexpression of the β-cell specific miRNA, miR-375, in pancreatic islets reduce insulin secretion [17] and reduced β-cell mass was detected in the miR-375 knock-out mouse as well as hyperglycaemia [19]. Since our model is characterized by altered miRNAs processing, including miR-375, it is likely that the reduced expression of miR-375 in RIP-Cre Dicer1Δ/Δ mice (Fig. 8B) contributes to diabetes development although it appears clear that other miRNAs have to be involved in the pathophysiology of these mice. It remains unclear whether miR-375 knock-out mice develop overt diabetes. In contrast, 100% of the RIP-Cre Dicer1Δ/Δ mice developed diabetes. Thus, a number of miRNAs, including miR-375, contribute to efficient β-cell function and protection from diabetes. Defining the miRNA network used by β-cells to maintain glucose homeostasis will be, in the future, very useful to design new therapeutic strategies to prevent and eventually reverse diabetes development.
Materials and Methods
Ethical statement
All experiments were performed in compliance with relevant Swedish and institutional laws and guidelines and were approved by the local ethics committee in Malmö (Malmö-Lund animal research ethics committee; M133-10 and M78-08).
Animals
Beta-cell specific Dicer1 deficient mice (RIP-Cre Dicer1Δ/Δ) were generated by crossing RIP-Cre+/− mice [37] with Dicer1 flox/flox mice, previously described [38], to obtain RIP-Cre+/− Dicer1Δ /wt which were then crossed with Dicer1 flox/flox mice. All mice used in the experiments carried the Cre transgene in heterozigosity and RIP-Cre+/− Dicer1Δ /wt littermates were used as control mice (control). All mice were maintained on a 12-h light/dark cycle and fed ad libitum with standard chow and tap water at Malmö University Hospital animal facility.
PCR
Dicer1 flox/flox genotype was determined using the following PCR primers (5′-3′): AGTGTAGCCTTAGCCATTTGC and CTGGTGGCTTGAGGACAAGAC, the wildtype (wt) allele giving a 259 bp and the floxed allele a 309 bp PCR product. The Cre allele was identified by a 675 bp large PCR product amplified using the TGCCACGACCAAGTGACAGC and CCAGGTTACGGATATAGTTCATG primers. Deletion of the Dicer1 exon 20–21 fragment was detected using the following PCR primers (5′-3′): AGTAATGTGAGCAATAGTCCCAG and CTGGTGGCTTGAGGACAAGAC, giving a product in both littermate controls and RIP-Cre Dicer1Δ/Δ mice of 309 bp. Complete deletion of Dicer1 exon 20–21 results in the absence of the 259 bp and the floxed allele a 309 bp PCR product bands in RIP-Cre Dicer1Δ/Δ mice.
Diabetes incidence
Mice were screened for blood glucose levels weekly starting from 3 weeks of age and were considered diabetic when glucose levels were ≥13.5 mmol/l on two consecutive measurements. The onset of diabetes was dated from the first of these sequential measurements. Tests were done at the same time daily to avoid variations due to feeding.
In vivo glucose tolerance test
Control mice (n = 6) and RIP-Cre Dicer1Δ/Δ mice were subjected to intraperitoneal glucose tolerance test (ipGTT) at 4–5 weeks of age and at 13 weeks of age. Mice were anaesthetised by i.p. injections of Hypnorm (0.315 mg/ml Fetanyl, 10 mg/ml Fluanisone, VetaPharma) and Dormicum (5 mg/ml, Roche AB, Stockholm) diluted four times in sterile water; 50 µl of the Hypnorm/Dormicum mix was first injected 15 minutes before experiment subcutaneously and then repeated every 20 minutes i.p. The body warmth was maintained by red lamp. Mice were injected intraperitoneally (i.p.) with 0.9% NaCl solution containing 2 mg D-glucose / 1 g body weight. Blood samples for glucose measurements were taken at 0, 5, 10, 15, 30, 60 and 120 minutes after the glucose load.
Islet isolation and in vitro insulin secretion assay
Mice were sacrificed by cervical dislocation and pancreatic islets were isolated by collagenase P digestion (Boehringer Mannheim, Bromma, Sweden). Insulin release in vitro was measured in static incubations [39]. Briefly, freshly isolated islets were preincubated for 30 minutes at 37°C in a Krebs-Ringer bicarbonate buffer supplemented with 1 mM glucose (pH 7.4). The medium was gassed with 95% O2 and 5% CO2 to obtain constant pH and oxygenation. Groups of 5 islets were then incubated in 0.2 ml Krebs-Ringer buffered solution supplemented with either 1 mM or 20 mM glucose for 60 minutes at 37°C. Immediately after incubation, an 80 µl aliquot of the medium was removed and the amount of secreted insulin was determined by ELISA (Rat Insulin ELISA-Kit, Mercodia, NC, USA). Insulin content was determined by RIA (radio immuno assay) after sonication and treatment with acid ethanol as previously described [39].
Transmission Electron Microscopy
Pancreatic islets were harvested from 2 week and 11 week old β-cell-specific RIP-Cre Dicer1Δ/Δ mice and their control littermates and fixated in 2.5% glutaraldehyde for 1 h at 4° C. Thereafter they were treated with 1% osmium tetroxide, dehydrated and embedded in Durcupan (Sigma, Sweden) before being cut into 70–90 nm ultrathin sections. The sections were put on Cu-grids and contrasted with uranyl acetate and lead citrate before examined in a JEM 1230 electron microscope (JEOL-USA. Inc., MA, USA). Micrographs were analysed with respect to the intracellular granular distribution using similar methods that have been described elsewhere [40]. The apparent diameter of individual LDCVs was determined with the image processing software Scion Image (NIH freeware). The LDCV volume density, the docked LDCV surface density and LDCV profiles were calculated using in-house software programmed in MatLab (Matlab7).
Histological and immunohistochemical analysis
After removal of the pancreata, one half of each pancreas was fixed with 4% formaldehyde and the other half rapidly frozen in Tissue-Tek® O.C.T.™ Compound (Sakura Finetek, Europe) on dry ice overnight, then stored at −80°C. Fixed tissues were processed for paraffin embedding. Serial 5 µm thick sections were prepared and stained. Paraffin-embedded sections were stained with hematoxylin/eosin (Sigma) to assess pancreatic islets histology and morphology in the experimental animals.
The immunofluorescence stainings were performed on paraffin sections or cryo sections. Paraffin sections were incubated with the following primary antibodies: guinea pig anti-insulin (1∶1000), guinea pig anti-glucagon (1∶600), rabbit anti-glucagon (1∶1000) (all from Eurodiagnostica, Malmö, Sweden) and rabbit anti-Ki67 (1∶200) (Novocastra Laboratories Ltd, Newcastle Upon Tyne, UK). Cryosections were fixed in acetone for 7 min, blocked with BSA and incubated with primary antibodies (or mixtures, if double-stained) at 4°C overnight, washed three times for 5 min in PBS, then incubated with FITC-conjugated anti guinea pig IgG (1∶200) and Cy3-conjugated anti-rabbit IgG (1∶300) (both from Jackson Immunoresearch Laboratories Inc, West Grove, PA) secondary antibodies for 45 minutes at room temperature. Cell nuclei were visualized after mounting with ProLong Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA, USA). Immunostainings were visualized using a Zeiss LSM510 Confocal microscope and laser excitations wavelengths of 488 nm and 543 nm. To control the specificities of the immunostaining procedures, the primary antibodies were replaced by normal serum from the appropriate species or by PBS. Quantification of insulin- and glucagon positive cells was measured using Zeiss LSM 510 program and was expressed as the ratio between insulin – and glucagon fluorescence in each islet.
Optical Projection Tomography (OPT)
The OPT technology was used to visualize the total ß-cells in the experimental pancreas. In brief, pancreas from RIP-Cre Dicer1Δ/Δ and control mice were dissected, cleaned of residual fat tissue and immediately submersed into freshly made 4% paraformaldehyde (Sigma P6148) in PBS for 3 h at 4°C, washed in PBS stepwise transferred to 100% methanol (MeOH) and stored at −20°C. Subsequently the pancreatic samples were stained with primary antibody Guinea Pig anti-Insulin (A0564, Dako) and secondary antibody goat anti GP Alexa Fluor 594 (A-11076, Invitrogen). OPT scannings of the pancreatic samples were carried out using the Bioptonics 3001 OPT M scanner (Bioptonics), with exciter D560/40× and emitter E610lpv2 filter (Chroma) as described previously [26]. Tomographic re-constructions were generated by using the NRecon V1.6.1.0 (Skyscan, Belgium) software and reconstructed images were further assessed using Bioptonics viewer V2.0 (Bioptonics) as previously described [26]. Further quantification for islet number was done using ImageJ 1.45n software. Briefly, image stack was opened using import/image sequence and saved as .avi file. After setting the scale globally the image channels were splitted and only the channel having the insulin staining was further used for quantitative analysis. This was first converted to 8 bit and then threshold was set to cover all the islets throughout the stack. 3D object counter plugin was used to count the number of islets. Possible artifacts were ruled out manually by using the synchronize tool and going through each slide to get the correct number of particles. The quantification of the beta cell volume was done by Volocity v5.2.1 (PerkinElmer) as per published method [26], [27]. Possible artifacts were omitted manually by going through slides to generate the correct beta cell volumes.
β-cell sorting
β-cell sorting was performed based on Newport Green-Ac staining as described by B. Lukowiak et al. with some modifications [41]. Briefly, islets from control littermates and RIP-Cre Dicer1Δ/Δ mice were incubated in a calcium-free buffer in 37°C for 12 minutes and then dissociated into single cell suspension by repeated pipetting. Islet cells were then incubated for 90 minutes in Opti-MEM minimal medium (Gibco, Invitrogen, Carlsbad, CA, USA) supplemented with 2.8 mM D-glucose and 1% L-glutamin. Subsequently, the cells were incubated with 1 µM Newport Green Ac-ester (Invitrogen, Carlsbad, CA, USA) and 1 µl/ml Pluronic F-127 dispersing agent (Invitrogen, Carlsbad, CA, USA) in 37°C for 30 minutes, to facilitate Ac-ester cell loading. Finally, cells were washed in indicator-free Opti-MEM medium and incubated for a further 30 minutes in 37°C to allow complete de-esterification of intra-cellular AM-esters. Newport Green-Ac stained islets cells were then subjected to cell sorting using a standard equipped fluorescence activated cell sorting (FACS) instrument (FACSaria, BD Biosciences, San Diego, CA, USA). Dead-cell discrimination was performed by staining cells with 7AAD (BD Pharmingen, USA). Cells were kept on ice during sorting procedures. Excitation was performed with the blue laser at 488 nm, and the high Newport Green positive cells were sorted in the Fl.1 channel. A fraction of sorted cells was placed on glass slides to confirm purity by immunofluorescence microscopy and viability while the rest of the cells were used for RNA purification as described below. Cell sorting analysis was performed using the Diva 6.1 software (BD Biosciences, San Diego, CA, USA).
Immunofluorescence microscopy of sorted β-cells
Sorted β-cells were cultured for 48 hours on cover glasses in RPMI 1640 (Gibco, Invitrogen) with Peni-Strep, 10% FCS and 1% L-glutamin to attach on the glass for later immunohistochemistry staining. Cell fractions were carefully washed with PBS after culture, and fixed with 4% paraformaldehyde for 20 minutes at room temperature. The cells were then permeabilized and blocked with PBS containing 0.1% Triton X-100 and 10% BSA for 45 minutes at room temperature. After blocking, the cells were incubated with 10 µg/ml monoclonal rat anti-mouse insulin IgG antibody (R&D Systems) in 4°C over night, followed by goat anti-rat IgG-Phycoerythrin secondary antibody / or goat anti-rat Alexa-456. Mounting was performed with ProLong Gold antifade reagent with DAPI (Invitrogen, Carlsbad, CA, USA).
Flow cytometry analysis of islet cells
Mouse islets were dissociated into cell suspension and fixed with Fixation/Permeabilization Buffer for 1.5 h, 4°C. After washing twice with Permeabilization/Wash Buffer (eBiosciences, San Diego, CA, USA), islet cells were stained with monoclonal rat-anti mouse insulin-phycoerythrin (PE) and/or monoclonal rat-anti mouse glucagon-allophycocyanin (APC) antibody (both from R&D Systems, MN, USA). Antibodies were direct-conjugated with Lightning Link-PE or APC (InnovaBiosciences, Cambridge, UK) for flow cytometry purposes before use. Islet cells were incubated in the dark with antibodies for 30 minutes at 4°C and then washed twice again with Permeabilization/Wash Buffer before resuspend them in staining buffer and acquired by flow cytometry on FACSCalibur Instrument and data were analyzed using CellQuest software (both from Becton Dickinson, San Jose, CA, USA).
Quantitative PCR (qPCR)
Total RNA from whole brain and FACS-sorted control and RIP-Cre Dicer1Δ/Δ-β-cells was extracted using the Qiagen miRNeasy isolation kit according to manufacturer's protocol (Qiagen, Hilden, Germany). The obtained RNA was quantified by NanoDrop ND-1000 (Thermo Fisher Scientific, USA) and subjected to reverse transcription using Quantitect Reverse Transcription Kit (Qiagen, Hilden, Germany), according to the manufacturer's suggested reaction conditions. qPCR was performed in triplicates using Taqman assays (Applied Biosystems, Foster City, CA, USA) for mouse insulin, mouse Dicer exon boundary 20–21, and mouse pri-miR-375. Mouse Hprt1 and cyclophilin were used as endogenous controls. For mature miR-375, stem-loop qPCR was performed normalized against snoRNA-202 and snoRNA-412. All runs were performed on ABI 7900 HT Fast Real-Time PCR Detection System (Applied Biosystems, Foster City, CA, USA).
Global microRNA expression profiling
Total RNA from sorted β-cells of wildtype, Dicer1flox/flox and RIP-Cre Dicer1Δ/Δ mice was extracted using the Qiagen miRNeasy isolation kit (Qiagen, Hilden, Germany). 50 ng of total RNA from each sample were labeled with the miRCURY™ Hy3™ dye using the accompanying kit and hybridized on the miRCURY™ LNA Array (v.11.0) according to manufacturer's protocol for Maui hybridisation chamber (Exiqon, Vedbaek, Denmark). Images were acquired using the Axon® GenePix 4000B scanner and GenePix software. After background subtraction from foreground signals, intensities within arrays were normalized using the loess normalization algorithm while quantile normalization was used between arrays as implemented in the web-fronted R-based array analysis tool, CARMAWeb 1.4. [42]. Only signals >50 were considered for analysis. The log2 values were used to generate heatmap using TreeView (http://jtreeview.sourceforge.net).
In situ Apoptosis detection
To identify apoptotic cells within the pancreatic islets, the Terminal Deoxynucleotidyl Transferase (TdT)-mediated dUTP end labelling (TUNEL) assay was used in paraffin embedded sections. The assay was performed accordingly to the manufacturer recommendation (TACS TdT-Fluorescein In Situ Apoptosis Detection Kit, R&D System Europe, Ltd, Abingdon, UK).” Nuclease-treated pancreas section from littermate control mice was used as positive control for TUNEL staining.
Statistical analysis
Differences in the incidence of diabetes were assessed using Kaplan–Meier analysis. Statistical significances of differences between means were estimated by Student's t-test. Values of P<0.05 were considered significant.
Supporting Information
Acknowledgments
The technical help of Lijun Zhao, Britt-Marie Nilsson, Anna-Maria Veljanovska Ramsayand Rita Wallén is appreciated. We thank Dr. Matthias Merkenschlager for sharing the Dicerlox/lox mice.
Footnotes
Competing Interests: The authors have declared that no competing interests exist.
Funding: This work was supported by the Swedish Research Council (project grants (LE and CC), collaboration grant (LE coordinator), CC and AW(PI:s)), Linneus grant to Lund University Diabetes Center (coordinator Leif Groop; LE and CC (PI:s), (JE co-PI)), EFSD-MSD, The Knut and Alice Wallenberg Foundation, The Marianne and Marcus Wallenberg Foundation, Novo Nordisk Foundation, The Swedish Diabetes Foundation, Albert Påhlssons Foundation, Magnus Bergwall Foundation, The Royal Physiographic Society in Lund, Lars Hiertas Minne Foundation, UMAS foundation and O. E. and Edla Johanssons Scientific Foundation. LE has a Senior Research position supported by the Swedish Research Council. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
References
- 1.Groop L. Pathogenesis of type 2 diabetes: the relative contribution of insulin resistance and impaired insulin secretion. Int J Clin Pract Suppl. 2000:3–13. [PubMed] [Google Scholar]
- 2.Wajchenberg BL. beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev. 2007;28:187–218. doi: 10.1210/10.1210/er.2006-0038. [DOI] [PubMed] [Google Scholar]
- 3.Goodge KA, Hutton JC. Translational regulation of proinsulin biosynthesis and proinsulin conversion in the pancreatic beta-cell. Semin Cell Dev Biol. 2000;11:235–242. doi: 10.1006/scdb.2000.0172. [DOI] [PubMed] [Google Scholar]
- 4.Andrali SS, Sampley ML, Vanderford NL, Ozcan S. Glucose regulation of insulin gene expression in pancreatic beta-cells. Biochem J. 2008;415:1–10. doi: 10.1042/BJ20081029. [DOI] [PubMed] [Google Scholar]
- 5.Lee EK, Gorospe M. Minireview: posttranscriptional regulation of the insulin and insulin-like growth factor systems. Endocrinology. 2010;151:1403–1408. doi: 10.1210/en.2009-1123. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Schnell AH, Swenne I, Borg LA. Lysosomes and pancreatic islet function. A quantitative estimation of crinophagy in the mouse pancreatic B-cell. Cell Tissue Res. 1988;252:9–15. doi: 10.1007/BF00213820. [DOI] [PubMed] [Google Scholar]
- 7.Olofsson CS, Gopel SO, Barg S, Galvanovskis J, Ma X, et al. Fast insulin secretion reflects exocytosis of docked granules in mouse pancreatic B-cells. Pflugers Arch. 2002;444:43–51. doi: 10.1007/s00424-002-0781-5. [DOI] [PubMed] [Google Scholar]
- 8.Daniel S, Noda M, Straub SG, Sharp GW. Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Diabetes. 1999;48:1686–1690. doi: 10.2337/diabetes.48.9.1686. [DOI] [PubMed] [Google Scholar]
- 9.Eliasson L, Abdulkader F, Braun M, Galvanovskis J, Hoppa MB, et al. Novel aspects of the molecular mechanisms controlling insulin secretion. J Physiol. 2008;586:3313–3324. doi: 10.1113/jphysiol.2008.155317. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Fabbri M, Croce CM, Calin GA. MicroRNAs. Cancer J. 2008;14:1–6. doi: 10.1097/PPO.0b013e318164145e. [DOI] [PubMed] [Google Scholar]
- 11.Sevignani C, Calin GA, Siracusa LD, Croce CM. Mammalian microRNAs: a small world for fine-tuning gene expression. Mamm Genome. 2006;17:189–202. doi: 10.1007/s00335-005-0066-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Ketting RF. Partners in dicing. Genome Biol. 2006;7:210. doi: 10.1186/gb-2006-7-3-210. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Bernstein E, Kim SY, Carmell MA, Murchison EP, Alcorn H, et al. Dicer is essential for mouse development. Nat Genet. 2003;35:215–217. doi: 10.1038/ng1253. [DOI] [PubMed] [Google Scholar]
- 14.Yang WJ, Yang DD, Na S, Sandusky GE, Zhang Q, et al. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem. 2005;280:9330–9335. doi: 10.1074/jbc.M413394200. [DOI] [PubMed] [Google Scholar]
- 15.Kanellopoulou C, Muljo SA, Kung AL, Ganesan S, Drapkin R, et al. Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing. Genes Dev. 2005;19:489–501. doi: 10.1101/gad.1248505. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.El Ouaamari A, Baroukh N, Martens GA, Lebrun P, Pipeleers D, et al. miR-375 targets PDK1 and regulates glucose-induced biological responses in pancreatic {beta}-cells. Diabetes. 2008 doi: 10.2337/db07-1614. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432:226–230. doi: 10.1038/nature03076. [DOI] [PubMed] [Google Scholar]
- 18.Bolmeson C, Esguerra JL, Salehi A, Speidel D, Eliasson L, et al. Differences in islet-enriched miRNAs in healthy and glucose intolerant human subjects. Biochem Biophys Res Commun. 2011;404:16–22. doi: 10.1016/j.bbrc.2010.11.024. [DOI] [PubMed] [Google Scholar]
- 19.Poy MN, Hausser J, Trajkovski M, Braun M, Collins S, et al. miR-375 maintains normal pancreatic alpha- and beta-cell mass. Proc Natl Acad Sci U S A. 2009;106:5813–5818. doi: 10.1073/pnas.0810550106. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Melkman-Zehavi T, Oren R, Kredo-Russo S, Shapira T, Mandelbaum AD, et al. miRNAs control insulin content in pancreatic beta-cells via downregulation of transcriptional repressors. EMBO J. 2011;30:835–845. doi: 10.1038/emboj.2010.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Lovis P, Gattesco S, Regazzi R. Regulation of the expression of components of the exocytotic machinery of insulin-secreting cells by microRNAs. Biol Chem. 2008;389:305–312. doi: 10.1515/BC.2008.026. [DOI] [PubMed] [Google Scholar]
- 22.Esguerra JL, Bolmeson C, Cilio CM, Eliasson L. Differential Glucose-Regulation of MicroRNAs in Pancreatic Islets of Non-Obese Type 2 Diabetes Model Goto-Kakizaki Rat. PLoS One. 2011;6:e18613. doi: 10.1371/journal.pone.0018613. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, et al. Alterations in microRNA expression contribute to fatty acid-induced pancreatic beta-cell dysfunction. Diabetes. 2008;57:2728–2736. doi: 10.2337/db07-1252. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Lynn FC, Skewes-Cox P, Kosaka Y, McManus MT, Harfe BD, et al. MicroRNA expression is required for pancreatic islet cell genesis in the mouse. Diabetes. 2007;56:2938–2945. doi: 10.2337/db07-0175. [DOI] [PubMed] [Google Scholar]
- 25.Song J, Xu Y, Hu X, Choi B, Tong Q. Brain expression of Cre recombinase driven by pancreas-specific promoters. Genesis. 2010;48:628–634. doi: 10.1002/dvg.20672. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Alanentalo T, Asayesh A, Morrison H, Loren CE, Holmberg D, et al. Tomographic molecular imaging and 3D quantification within adult mouse organs. Nat Methods. 2007;4:31–33. doi: 10.1038/nmeth985. [DOI] [PubMed] [Google Scholar]
- 27.Alanentalo T, Hornblad A, Mayans S, Karin Nilsson A, Sharpe J, et al. Quantification and three-dimensional imaging of the insulitis-induced destruction of beta-cells in murine type 1 diabetes. Diabetes. 2010;59:1756–1764. doi: 10.2337/db09-1400. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Bravo-Egana V, Rosero S, Molano RD, Pileggi A, Ricordi C, et al. Quantitative differential expression analysis reveals miR-7 as major islet microRNA. Biochem Biophys Res Commun. 2008;366:922–926. doi: 10.1016/j.bbrc.2007.12.052. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Cheloufi S, Dos Santos CO, Chong MM, Hannon GJ. A dicer-independent miRNA biogenesis pathway that requires Ago catalysis. Nature. 2010;465:584–589. doi: 10.1038/nature09092. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cifuentes D, Xue H, Taylor DW, Patnode H, Mishima Y, et al. A novel miRNA processing pathway independent of Dicer requires Argonaute2 catalytic activity. Science. 2010;328:1694–1698. doi: 10.1126/science.1190809. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Morita S, Hara A, Kojima I, Horii T, Kimura M, et al. Dicer is required for maintaining adult pancreas. PLoS ONE. 2009;4:e4212. doi: 10.1371/journal.pone.0004212. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Gannon M, Shiota C, Postic C, Wright CV, Magnuson M. Analysis of the Cre-mediated recombination driven by rat insulin promoter in embryonic and adult mouse pancreas. Genesis. 2000;26:139–142. doi: 10.1002/(sici)1526-968x(200002)26:2<139::aid-gene12>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
- 33.Jonsson J, Carlsson L, Edlund T, Edlund H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 1994;371:606–609. doi: 10.1038/371606a0. [DOI] [PubMed] [Google Scholar]
- 34.Gittes GK, Rutter WJ. Onset of cell-specific gene expression in the developing mouse pancreas. Proc Natl Acad Sci U S A. 1992;89:1128–1132. doi: 10.1073/pnas.89.3.1128. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Kolfschoten IG, Roggli E, Nesca V, Regazzi R. Role and therapeutic potential of microRNAs in diabetes. Diabetes Obes Metab. 2009;11(Suppl 4):118–129. doi: 10.1111/j.1463-1326.2009.01118.x. [DOI] [PubMed] [Google Scholar]
- 36.Hennessy E, O'Driscoll L. Molecular medicine of microRNAs: structure, function and implications for diabetes. Expert Rev Mol Med. 2008;10:e24. doi: 10.1017/S1462399408000781. [DOI] [PubMed] [Google Scholar]
- 37.Herrera PL. Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages. Development. 2000;127:2317–2322. doi: 10.1242/dev.127.11.2317. [DOI] [PubMed] [Google Scholar]
- 38.Cobb BS, Nesterova TB, Thompson E, Hertweck A, O'Connor E, et al. T cell lineage choice and differentiation in the absence of the RNase III enzyme Dicer. J Exp Med. 2005;201:1367–1373. doi: 10.1084/jem.20050572. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Salehi A, Henningsson R, Mosen H, Ostenson CG, Efendic S, et al. Dysfunction of the islet lysosomal system conveys impairment of glucose-induced insulin release in the diabetic GK rat. Endocrinology. 1999;140:3045–3053. doi: 10.1210/endo.140.7.6862. [DOI] [PubMed] [Google Scholar]
- 40.Vikman J, Jimenez-Feltstrom J, Nyman P, Thelin J, Eliasson L. Insulin secretion is highly sensitive to desorption of plasma membrane cholesterol. FASEB J. 2009;23:58–67. doi: 10.1096/fj.08-105734. [DOI] [PubMed] [Google Scholar]
- 41.Lukowiak B, Vandewalle B, Riachy R, Kerr-Conte J, Gmyr V, et al. Identification and purification of functional human beta-cells by a new specific zinc-fluorescent probe. J Histochem Cytochem. 2001;49:519–528. doi: 10.1177/002215540104900412. [DOI] [PubMed] [Google Scholar]
- 42.Rainer J, Sanchez-Cabo F, Stocker G, Sturn A, Trajanoski Z. CARMAweb: comprehensive R- and bioconductor-based web service for microarray data analysis. Nucleic Acids Res. 2006;34:W498–503. doi: 10.1093/nar/gkl038. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.